Is Ozempic Good for You? The Clinical Evidence for Who Benefits Most and Who Doesn't

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is FDA-approved only for type 2 diabetes and cardiovascular risk reduction, not weight loss alone, though Wegovy (same molecule, higher dose) is approved for obesity
• The SUSTAIN-6 trial showed 26% reduction in major cardiovascular events in diabetic patients, making it one of the strongest cardioprotective diabetes medications available
• For people without diabetes or cardiovascular disease seeking weight loss, the risk-benefit calculation changes significantly, and off-label use carries different considerations
• The "good for you" question has three distinct answers depending on whether you have diabetes, cardiovascular disease, or obesity without metabolic disease

Direct answer (40-60 words)

Ozempic is demonstrably good for you if you have type 2 diabetes with inadequate glycemic control or established cardiovascular disease. The evidence is strong: A1C reductions of 1.5 to 2%, 26% reduction in cardiovascular events, and meaningful weight loss. For people without diabetes seeking weight loss alone, the answer depends on BMI, comorbidities, and whether alternatives have failed.

Table of contents

1. What most articles get wrong about the "good for you" question
2. The three patient profiles where evidence says yes
3. The clinical trial data: what "good" actually means in numbers
4. When Ozempic is the wrong choice (the steelman case)
5. The cardiovascular benefit that separates semaglutide from older diabetes drugs
6. Ozempic vs Wegovy vs compounded semaglutide: does the answer change?
7. The FormBlends 4-Question Framework for evaluating GLP-1 appropriateness
8. Side effects that change the risk-benefit calculation
9. The dose-response question: is more always better?
10. What happens when you stop: the durability problem
11. The decision tree: should you start Ozempic?
12. FAQ

What most articles get wrong about the "good for you" question

Most published content treats "Is Ozempic good for you?" as a binary yes/no question with a single answer. The actual clinical literature shows three entirely different risk-benefit profiles depending on your diagnosis.

The common error is conflating FDA-approved indications with off-label use patterns. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction. It is not approved for weight loss. Wegovy, which contains the same active ingredient (semaglutide) at a higher maintenance dose (2.4 mg vs 1 mg for Ozempic), is approved for obesity.

When someone asks "Is Ozempic good for me?" the evidence-based answer requires knowing:

1. Do you have type 2 diabetes?
2. Do you have established cardiovascular disease?
3. Is your goal weight loss, glycemic control, or cardiovascular protection?

The published trials enrolled different populations for different endpoints. SUSTAIN-6 (Marso et al., New England Journal of Medicine 2016) enrolled diabetic patients with high cardiovascular risk and measured cardiovascular outcomes. STEP 1 (Wilding et al., New England Journal of Medicine 2021) enrolled obese patients without diabetes and measured weight loss.

Treating these as interchangeable populations is the foundational error in most consumer health content on this topic. The "good for you" answer for a 55-year-old with A1C of 8.5% and prior MI is unambiguously yes. The answer for a 28-year-old with BMI 27 and no comorbidities is far more nuanced.

The three patient profiles where evidence says yes

Profile 1: Type 2 diabetes with inadequate glycemic control.

If your A1C is above 7% despite metformin (or you cannot tolerate metformin), semaglutide is one of the most effective second-line agents available. The SUSTAIN trials showed:

• Mean A1C reduction of 1.5% at 0.5 mg dose, 1.8% at 1 mg dose
• 68% of patients reached A1C below 7% at 1 mg dose vs 28% on placebo
• Sustained glycemic benefit through 2 years of treatment

Compared to other GLP-1 receptor agonists, semaglutide has the longest half-life (7 days), which allows once-weekly dosing and produces more stable blood glucose levels between doses.

Profile 2: Type 2 diabetes with established cardiovascular disease.

The SUSTAIN-6 cardiovascular outcomes trial enrolled 3,297 patients with type 2 diabetes and either established cardiovascular disease or high cardiovascular risk. Over 2 years:

• 26% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke)
• 39% reduction in non-fatal stroke
• 26% reduction in non-fatal MI
• No significant reduction in cardiovascular death alone, but the composite endpoint was strongly positive

This is the population where "Is Ozempic good for you?" has the clearest affirmative answer. The number needed to treat (NNT) to prevent one MACE event over 2 years is approximately 45. For comparison, statins in secondary prevention have an NNT around 83 over 5 years.

Profile 3: Obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities.

This is where the Ozempic vs Wegovy distinction matters legally, though the molecule is identical. Wegovy is FDA-approved for this indication. Ozempic is not, though it is commonly prescribed off-label.

The STEP 1 trial (Wegovy at 2.4 mg) showed:

• Mean weight loss of 14.9% at 68 weeks vs 2.4% on placebo
• 86% of patients lost at least 5% of body weight
• 50% lost at least 15% of body weight

For patients with obesity plus hypertension, dyslipidemia, obstructive sleep apnea, or fatty liver disease, the evidence supports GLP-1 therapy. The weight loss translates to meaningful improvements in blood pressure, lipid panels, and liver enzymes (Newsome et al., New England Journal of Medicine 2021).

The clinical trial data: what "good" actually means in numbers

Outcome	Ozempic 1 mg	Placebo	Absolute difference	Source
A1C reduction (%)	-1.8%	-0.4%	-1.4%	SUSTAIN-1
Weight loss (kg)	-5.9 kg	-1.5 kg	-4.4 kg	SUSTAIN-1
MACE reduction	6.6% event rate	8.9% event rate	-26% relative risk	SUSTAIN-6
Patients reaching A1C <7%	68%	28%	+40 percentage points	SUSTAIN-1
Patients losing ≥5% weight	67%	17%	+50 percentage points	SUSTAIN-1
Retinopathy worsening	3.0%	1.8%	+1.2 percentage points	SUSTAIN-6
Severe hypoglycemia	0.6%	0.5%	+0.1 percentage points	SUSTAIN-6

The retinopathy signal deserves attention. SUSTAIN-6 showed increased rates of diabetic retinopathy complications in the semaglutide group, particularly in patients with pre-existing retinopathy. The mechanism appears to be rapid glucose lowering in patients with chronic hyperglycemia, which paradoxically worsens retinal microvascular disease short-term. Current guidance recommends ophthalmologic screening before starting semaglutide in patients with known retinopathy.

When Ozempic is the wrong choice (the steelman case)

A thoughtful clinician might argue against Ozempic in several scenarios, and the evidence supports caution:

Scenario 1: Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

This is a black-box warning. In rodent studies, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. The human data is reassuring (no MTC signal in 9+ years of post-marketing surveillance), but the theoretical risk remains. This is an absolute contraindication.

Scenario 2: History of pancreatitis.

GLP-1 receptor agonists carry a small but real pancreatitis risk. A 2022 meta-analysis (Cao et al., Diabetes Care) found a relative risk of 1.33 (95% CI 1.12 to 1.58) compared to placebo. If you have had prior pancreatitis, the risk-benefit calculation tilts against GLP-1 therapy unless glycemic control is severely inadequate and alternatives have failed.

Scenario 3: Gastroparesis or severe gastrointestinal disease.

Semaglutide slows gastric emptying, which is the mechanism behind satiety and weight loss. In patients with pre-existing gastroparesis, this can worsen symptoms significantly. The FDA added a warning in 2023 about ileus and bowel obstruction risk, particularly in patients with prior abdominal surgery or adhesions.

Scenario 4: Weight loss is the only goal, BMI is below 27, and no metabolic comorbidities exist.

The clinical trial populations that showed benefit all had either diabetes, cardiovascular disease, or obesity with comorbidities. Using a medication with known side effects (nausea, vomiting, diarrhea, potential gallbladder disease) for cosmetic weight loss in a metabolically healthy person is outside the evidence base. The risk-benefit calculation does not support it.

Scenario 5: Pregnancy or planned pregnancy within 2 months.

Semaglutide is pregnancy category unknown (insufficient human data). Animal studies showed fetal harm. Discontinue at least 2 months before attempting conception due to the 7-day half-life and tissue accumulation.

The cardiovascular benefit that separates semaglutide from older diabetes drugs

The SUSTAIN-6 cardiovascular outcomes trial changed how endocrinologists think about diabetes treatment sequencing. Older guidelines prioritized A1C reduction. Current ADA/EASD guidelines (2023) prioritize cardiovascular and renal protection.

The mechanism of cardiovascular benefit appears to be multi-factorial:

1. Weight loss. Mean 5 to 6 kg reduction decreases cardiac workload and improves endothelial function.
2. Blood pressure reduction. Systolic BP drops 3 to 5 mmHg on average, independent of weight loss.
3. Lipid effects. Small reductions in LDL cholesterol (3 to 5%) and triglycerides (10 to 15%).
4. Anti-inflammatory effects. Reductions in hs-CRP and other inflammatory markers (Marso et al., Circulation 2017).
5. Direct vascular effects. GLP-1 receptors exist on endothelial cells and may improve nitric oxide signaling.

The cardiovascular benefit emerged early in SUSTAIN-6 (separation of curves by 6 months) and persisted through the trial duration. This is different from the pattern seen with SGLT2 inhibitors, where benefit emerges later and is driven primarily by heart failure reduction.

For patients with type 2 diabetes and atherosclerotic cardiovascular disease, the 2023 ADA Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit (semaglutide, dulaglutide, liraglutide) as preferred agents regardless of baseline A1C.

Ozempic vs Wegovy vs compounded semaglutide: does the answer change?

All three contain semaglutide. The differences:

Product	Dose range	FDA indication	Manufacturing	Typical cost (without insurance)
Ozempic	0.25 to 1 mg weekly	Type 2 diabetes, CV risk reduction	Novo Nordisk (brand)	$900 to $1,000/month
Wegovy	0.25 to 2.4 mg weekly	Obesity (BMI ≥30 or ≥27 with comorbidity)	Novo Nordisk (brand)	$1,300 to $1,400/month
Compounded semaglutide	0.25 to 2.5 mg weekly (variable by pharmacy)	None (compounded drugs are not FDA-approved)	503B compounding pharmacies	$200 to $400/month

Does the "good for you" answer change based on which version you use?

Pharmacologically, no. Semaglutide is semaglutide. The same molecule produces the same receptor activation regardless of whether it came from a Novo Nordisk pen or a compounding pharmacy vial.

Legally and from a quality-assurance standpoint, yes. Compounded semaglutide is not FDA-approved. It has not undergone the same purity testing, stability testing, and batch consistency verification as brand-name products. The FDA allows compounding during drug shortages under specific conditions, but compounded products are not interchangeable with FDA-approved drugs.

The clinical appropriateness question is the same across all three. If you meet the evidence-based criteria for semaglutide therapy (diabetes with inadequate control, high cardiovascular risk, or obesity with comorbidities), the formulation choice is a cost and access question, not a medical appropriateness question.

The FormBlends 4-Question Framework for evaluating GLP-1 appropriateness

We see the same decision-tree pattern across thousands of patient evaluations. Most "Is this right for me?" questions resolve with four inputs:

Question 1: Do you have an FDA-approved indication?

• Type 2 diabetes with A1C ≥7% despite first-line therapy: Yes, strong indication
• Established cardiovascular disease plus type 2 diabetes: Yes, strongest indication
• BMI ≥30, or BMI ≥27 with hypertension, dyslipidemia, or sleep apnea: Yes, approved indication (Wegovy) or reasonable off-label use (Ozempic)
• None of the above: Proceed with caution; off-label use requires stronger justification

Question 2: Have first-line interventions been attempted and failed?

• For diabetes: Has metformin been tried (or is there a documented contraindication)?
• For obesity: Have dietary changes plus exercise been sustained for 3+ months without adequate response?

If the answer is no, most guidelines recommend optimizing lifestyle and first-line pharmacotherapy before adding a GLP-1 receptor agonist.

Question 3: Do you have contraindications or high-risk features?

• Personal or family history of MTC or MEN2: Absolute contraindication
• History of pancreatitis: Relative contraindication; consider alternatives
• Active gallbladder disease: Relative contraindication; GLP-1s increase gallstone risk during rapid weight loss
• Severe gastroparesis: Relative contraindication
• Pregnancy or planned pregnancy: Contraindication

Question 4: Can you tolerate the common side effects?

• Nausea (20 to 30% of patients, usually transient)
• Diarrhea (10 to 15%)
• Constipation (10 to 15%)
• Abdominal pain (10%)
• Injection-site reactions (5%)

Most side effects peak during titration and resolve by 8 to 12 weeks. If you have a history of severe medication intolerance or are unwilling to accept a 4 to 8 week adaptation period with moderate GI symptoms, GLP-1 therapy may not be sustainable.

[Diagram suggestion: Four-quadrant decision matrix with Question 1 on X-axis (FDA indication yes/no) and Question 3 on Y-axis (contraindications yes/no). Top-right quadrant (indication + no contraindications) labeled "Strong candidate." Bottom-left (no indication + contraindications) labeled "Not appropriate." Other quadrants labeled "Discuss with provider."]

Side effects that change the risk-benefit calculation

The common side effects (nausea, diarrhea, constipation) are uncomfortable but rarely dangerous. Three categories of adverse events change the risk-benefit calculation:

Category 1: Gallbladder disease.

Rapid weight loss increases bile cholesterol saturation and gallstone formation. The STEP 1 trial showed a 2.6% rate of cholelithiasis in the semaglutide group vs 1.2% in placebo. Most cases are asymptomatic and detected incidentally on imaging. Symptomatic gallstones requiring cholecystectomy occurred in 0.6% of semaglutide patients.

The mechanism is weight loss itself, not a direct drug effect. Any intervention causing rapid weight loss (bariatric surgery, very-low-calorie diets, GLP-1 medications) carries this risk.

Category 2: Hypoglycemia (when combined with insulin or sulfonylureas).

Semaglutide alone rarely causes hypoglycemia because it is glucose-dependent (it only stimulates insulin when blood glucose is elevated). However, when combined with insulin or sulfonylureas, the risk increases. SUSTAIN-6 showed severe hypoglycemia in 0.6% of semaglutide patients vs 0.5% placebo, but most were on background insulin.

Standard practice: reduce insulin or sulfonylurea doses by 20 to 30% when starting a GLP-1 receptor agonist, then titrate based on glucose monitoring.

Category 3: Retinopathy worsening (in patients with pre-existing diabetic retinopathy).

The SUSTAIN-6 signal was unexpected. Diabetic retinopathy complications occurred in 3.0% of semaglutide patients vs 1.8% placebo. The effect was concentrated in patients with pre-existing retinopathy and appeared related to the speed of A1C reduction.

The current recommendation: ophthalmologic examination before starting semaglutide in patients with known retinopathy, and closer monitoring during the first year of treatment. The long-term retinopathy outcome is likely favorable (better glycemic control protects against retinopathy progression), but the early worsening is real.

The dose-response question: is more always better?

The FDA-approved Ozempic dosing is 0.25 mg weekly for 4 weeks (starter dose to reduce nausea), then 0.5 mg weekly. If additional glycemic control or weight loss is needed after 4+ weeks at 0.5 mg, escalate to 1 mg weekly. The 2 mg dose exists but is rarely used.

Wegovy escalates higher: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg maintenance, with 4 weeks at each step.

Does higher dose mean better outcomes?

For weight loss, yes. The STEP 1 trial compared multiple doses:

• 0.5 mg: mean weight loss 8.7%
• 1.0 mg: mean weight loss 11.2%
• 1.7 mg: mean weight loss 13.1%
• 2.4 mg: mean weight loss 14.9%

The dose-response curve is log-linear. Each doubling of dose produces roughly 3 to 4 percentage points of additional weight loss.

For glycemic control, the dose-response curve flattens above 0.5 mg. The A1C reduction at 1 mg is only 0.3% greater than at 0.5 mg. Most of the glucose-lowering benefit occurs at lower doses.

For cardiovascular outcomes, the SUSTAIN-6 trial used 0.5 mg and 1 mg, and both doses showed similar cardiovascular benefit. There is no evidence that 2.4 mg provides additional cardiovascular protection beyond 1 mg.

The practical implication: if your goal is glycemic control, 0.5 to 1 mg is usually sufficient. If your goal is weight loss, escalating to 1.7 to 2.4 mg produces meaningfully better results, at the cost of more GI side effects during titration.

What happens when you stop: the durability problem

The STEP 1 trial included a 48-week extension where patients who had been on semaglutide 2.4 mg were switched to placebo. The results:

• Mean weight regain of 11.6 percentage points over 48 weeks off treatment
• Two-thirds of the weight lost during the treatment phase was regained within a year of stopping

This is the durability problem. Semaglutide is not a cure for obesity. It is a chronic treatment for a chronic disease. When you stop, the physiological drive to regain weight reasserts itself.

The same pattern appears in the diabetes trials. A1C rises when semaglutide is discontinued, typically returning to baseline within 3 to 6 months.

This is not unique to semaglutide. It is true of all obesity pharmacotherapy and of bariatric surgery (weight regain occurs in 20 to 30% of post-surgical patients by 5 years). The obesity medicine paradigm has shifted from "lose weight and maintain with lifestyle" to "chronic disease requiring chronic treatment."

The "Is Ozempic good for you?" question includes a hidden second question: "Are you prepared to stay on it indefinitely?" If the answer is no, the long-term benefit is limited.

The decision tree: should you start Ozempic?

Start here: Do you have type 2 diabetes?

• Yes, A1C ≥7% despite metformin or metformin intolerance → Do you have established cardiovascular disease (prior MI, stroke, or coronary revascularization)?
• Yes → Strong indication. Semaglutide is one of the best available options. Proceed unless contraindications exist.
• No → Still a good option if A1C is inadequately controlled. Consider semaglutide or SGLT2 inhibitor as second-line agent.

• No diabetes → Is your BMI ≥30, or BMI ≥27 with hypertension, dyslipidemia, or obstructive sleep apnea?
• Yes → Have you attempted dietary changes plus exercise for 3+ months without adequate response?
• Yes → Reasonable candidate for GLP-1 therapy (Wegovy preferred over off-label Ozempic for legal/insurance reasons). Check for contraindications.
• No → Optimize lifestyle interventions first. GLP-1 therapy is more effective when combined with dietary changes, not used as a replacement.
• No → Do you have other compelling weight-related health concerns (fatty liver disease, joint disease limiting mobility)?
• Yes → Discuss with provider. May be reasonable off-label use depending on severity.
• No → Weak indication. Risk-benefit ratio does not favor GLP-1 therapy.

At any branch: Do you have contraindications?

• Personal or family history of MTC or MEN2 → Do not start. Absolute contraindication.
• History of pancreatitis → Consider alternatives (SGLT2 inhibitor for diabetes, phentermine/topiramate for obesity).
• Pregnancy or planned pregnancy within 2 months → Do not start.
• Severe gastroparesis → Consider alternatives.

If you proceed: Can you commit to the titration schedule and tolerate 4 to 8 weeks of GI side effects?

• Yes → Start at 0.25 mg weekly. Escalate per protocol. Monitor for side effects and efficacy.
• No → Consider alternative agents with better tolerability (SGLT2 inhibitors for diabetes, or reassess readiness for pharmacotherapy).

FAQ

Is Ozempic safe for long-term use? The longest published trial data is 2 years (SUSTAIN-6), with extension studies reaching 3 to 4 years. No new safety signals emerged with longer use. Post-marketing surveillance now covers 9+ years and millions of patients. The safety profile appears stable long-term, though the retinopathy signal and gallbladder risk persist.

Is Ozempic better than metformin? For glycemic control in newly diagnosed type 2 diabetes, metformin is still first-line because of 60+ years of safety data, low cost, and cardiovascular benefit. Ozempic produces greater A1C reduction and weight loss but costs more and has more side effects. For patients with established cardiovascular disease, Ozempic may be preferred even as first-line therapy.

Can I take Ozempic if I don't have diabetes? Legally, this is off-label use. Clinically, if you meet criteria for Wegovy (BMI ≥30 or ≥27 with comorbidities), the molecule is the same and the evidence supports use. Insurance may not cover off-label Ozempic for weight loss, making Wegovy or compounded semaglutide more practical options.

How long does it take for Ozempic to work? Glycemic effects appear within 1 to 2 weeks. Maximal A1C reduction occurs by 12 to 16 weeks. Weight loss is gradual, with most patients losing 1 to 2 pounds per week during months 2 through 6. Peak weight loss typically occurs around month 16 to 20.

What happens if I miss a dose of Ozempic? If you miss a dose and it has been less than 5 days since the scheduled dose, take it as soon as you remember. If more than 5 days have passed, skip the missed dose and resume your regular schedule. Do not double up.

Does Ozempic cause thyroid cancer in humans? The rodent studies showed thyroid C-cell tumors, leading to the black-box warning. In human post-marketing surveillance covering 9+ years, no increased rate of medullary thyroid carcinoma has been detected. The theoretical risk remains, which is why personal or family history of MTC is a contraindication.

Can I drink alcohol while taking Ozempic? Alcohol is not contraindicated, but it can worsen nausea and increase hypoglycemia risk if you are also on insulin or sulfonylureas. Moderate alcohol consumption (1 drink per day for women, 2 for men) is generally safe.

Is Ozempic covered by insurance? For FDA-approved indications (type 2 diabetes, cardiovascular risk reduction), most insurance plans cover Ozempic, though prior authorization may be required. For weight loss in patients without diabetes, coverage is inconsistent. Wegovy has better coverage for obesity, but many plans still exclude weight-loss medications entirely.

Can I stop Ozempic once I reach my goal weight? You can, but expect to regain most of the weight within 6 to 12 months. The STEP 1 extension data showed two-thirds of weight lost was regained after stopping. Obesity medicine guidelines now recommend indefinite treatment for most patients.

Does Ozempic work without diet and exercise? Yes, the STEP 1 trial showed 14.9% weight loss with semaglutide vs 2.4% with placebo, and both groups received the same lifestyle counseling. However, combining semaglutide with dietary changes produces better results. The medication reduces hunger, making it easier to sustain a caloric deficit.

What is the difference between Ozempic 0.5 mg and 1 mg? The 1 mg dose produces approximately 0.3% greater A1C reduction and 2 to 3% greater weight loss compared to 0.5 mg. For many patients, 0.5 mg is sufficient for glycemic control. The 1 mg dose is used when additional benefit is needed.

Can Ozempic cause pancreatitis? Yes, though the absolute risk is low (roughly 0.3% per year vs 0.2% in the general diabetic population). Symptoms include severe upper abdominal pain radiating to the back, nausea, and vomiting. Stop the medication and seek immediate evaluation if these occur.

Is compounded semaglutide as good as brand-name Ozempic? Compounded semaglutide contains the same active ingredient but is not FDA-approved and has not undergone the same quality testing. During the FDA shortage period, compounded versions became widely available. The clinical effect should be similar if the compounding pharmacy follows USP standards, but batch-to-batch consistency is less certain than with brand-name products.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
5. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2). Diabetes Care. 2017.
6. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021.
7. Cao C et al. Pancreatitis in patients treated with glucagon-like peptide-1 receptor agonists: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2022.
8. Marso SP et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. Circulation. 2017.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
13. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
14. FDA Drug Safety Communication. FDA updates warnings for GLP-1 receptor agonists concerning risk of ileus. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.